The novel implant is the only FDA-approved device to reduce stroke risk in patients with atrial fibrillation not caused by a heart valve problem, or non-valvular atrial fibrillation.
The device offers non-valvular AF patients an alternative to lifelong use of warfarin, a standard-of-care blood thinner linked to bleeding complications. Currently, half of AF patients who are eligible for warfarin are untreated due to tolerance and adherence issues.
“The device is a novel alternative for patients with non-valvular Afib at risk for a stroke, especially those with a compelling reason not to be on blood thinners,” said Alfred Danielian, MD, medical director of echocardiography and director of sports cardiology at Las Vegas Heart Associates, who helped perform the procedure.
The device works by closing off the left atrial appendage to keep out blood clots that could eventually cause a stroke. Over time, this could reduce stroke risk and allow patients to stop taking warfarin.
More articles on cardiology:
About 40% of critical heart patients missing care, South Dakota cardiologist says
Mayo cardiologist inducted into National Academy of inventors
Atrium Health to open pediatric heart center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.